These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Alpha-synuclein in Lewy bodies. Spillantini MG; Schmidt ML; Lee VM; Trojanowski JQ; Jakes R; Goedert M Nature; 1997 Aug; 388(6645):839-40. PubMed ID: 9278044 [No Abstract] [Full Text] [Related]
23. Astrocytes and retrograde degeneration of nigrostriatal dopaminergic neurons in Parkinson's disease: removing axonal debris. Morales I; Puertas-Avendaño R; Sanchez A; Perez-Barreto A; Rodriguez-Sabate C; Rodriguez M Transl Neurodegener; 2021 Nov; 10(1):43. PubMed ID: 34727977 [TBL] [Abstract][Full Text] [Related]
24. Necroptosis increases with age in the brain and contributes to age-related neuroinflammation. Thadathil N; Nicklas EH; Mohammed S; Lewis TL; Richardson A; Deepa SS Geroscience; 2021 Oct; 43(5):2345-2361. PubMed ID: 34515928 [TBL] [Abstract][Full Text] [Related]
25. RIPK1 or RIPK3 deletion prevents progressive neuronal cell death and improves memory function after traumatic brain injury. Wehn AC; Khalin I; Duering M; Hellal F; Culmsee C; Vandenabeele P; Plesnila N; Terpolilli NA Acta Neuropathol Commun; 2021 Aug; 9(1):138. PubMed ID: 34404478 [TBL] [Abstract][Full Text] [Related]
26. Parkinson's disease risk genes act in glia to control neuronal α-synuclein toxicity. Olsen AL; Feany MB Neurobiol Dis; 2021 Nov; 159():105482. PubMed ID: 34390834 [TBL] [Abstract][Full Text] [Related]
27. The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses. Jan A; Gonçalves NP; Vaegter CB; Jensen PH; Ferreira N Int J Mol Sci; 2021 Aug; 22(15):. PubMed ID: 34361100 [TBL] [Abstract][Full Text] [Related]
33. Targeting Microglial α-Synuclein/TLRs/NF-kappaB/NLRP3 Inflammasome Axis in Parkinson's Disease. Li Y; Xia Y; Yin S; Wan F; Hu J; Kou L; Sun Y; Wu J; Zhou Q; Huang J; Xiong N; Wang T Front Immunol; 2021; 12():719807. PubMed ID: 34691027 [TBL] [Abstract][Full Text] [Related]
34. Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment. Li S; Qu L; Wang X; Kong L Pharmacol Ther; 2022 Mar; 231():107979. PubMed ID: 34480965 [TBL] [Abstract][Full Text] [Related]
35. α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Ca Leandrou E; Chalatsa I; Anagnostou D; Machalia C; Semitekolou M; Filippa V; Makridakis M; Vlahou A; Anastasiadou E; Vekrellis K; Emmanouilidou E Transl Neurodegener; 2024 Feb; 13(1):11. PubMed ID: 38378800 [TBL] [Abstract][Full Text] [Related]
36. Alpha-Synuclein Contribution to Neuronal and Glial Damage in Parkinson's Disease. Saramowicz K; Siwecka N; Galita G; Kucharska-Lusina A; Rozpędek-Kamińska W; Majsterek I Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203531 [TBL] [Abstract][Full Text] [Related]
37. MLKL deficiency alleviates neuroinflammation and motor deficits in the α-synuclein transgenic mouse model of Parkinson's disease. Geng L; Gao W; Saiyin H; Li Y; Zeng Y; Zhang Z; Li X; Liu Z; Gao Q; An P; Jiang N; Yu X; Chen X; Li S; Chen L; Lu B; Li A; Chen G; Shen Y; Zhang H; Tian M; Zhang Z; Li J Mol Neurodegener; 2023 Dec; 18(1):94. PubMed ID: 38041169 [TBL] [Abstract][Full Text] [Related]
38. RIPK3 promotes brain region-specific interferon signaling and restriction of tick-borne flavivirus infection. Lindman M; Angel JP; Estevez I; Chang NP; Chou TW; McCourt M; Atkins C; Daniels BP PLoS Pathog; 2023 Nov; 19(11):e1011813. PubMed ID: 38011306 [TBL] [Abstract][Full Text] [Related]
39. Astrocytes in Parkinson's Disease: From Role to Possible Intervention. Wang T; Sun Y; Dettmer U Cells; 2023 Sep; 12(19):. PubMed ID: 37830550 [TBL] [Abstract][Full Text] [Related]
40. KDM2B regulates inflammation and oxidative stress of sepsis via targeting NF-κB and AP-1 pathways. Li X; Tian X; Zhang D Immun Inflamm Dis; 2023 Sep; 11(9):e985. PubMed ID: 37773725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]